Free Trial
NASDAQ:CRNX

Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis

Crinetics Pharmaceuticals logo
$30.92 +1.52 (+5.17%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$30.95 +0.03 (+0.11%)
As of 08/22/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)

Key Stats

Today's Range
$29.63
$31.70
50-Day Range
$26.85
$33.02
52-Week Range
$24.10
$62.53
Volume
1.36 million shs
Average Volume
1.00 million shs
Market Capitalization
$2.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.86
Consensus Rating
Moderate Buy

Company Overview

Crinetics Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

CRNX MarketRank™: 

Crinetics Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 268th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Crinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Crinetics Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Crinetics Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.73) to ($4.11) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Crinetics Pharmaceuticals is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Crinetics Pharmaceuticals is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Crinetics Pharmaceuticals has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Crinetics Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    14.66% of the float of Crinetics Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Crinetics Pharmaceuticals has recently increased by 7.60%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Crinetics Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Crinetics Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.66% of the float of Crinetics Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Crinetics Pharmaceuticals has recently increased by 7.60%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Crinetics Pharmaceuticals has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Crinetics Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    11 people have searched for CRNX on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,331,314.00 in company stock.

  • Percentage Held by Insiders

    Only 4.60% of the stock of Crinetics Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Crinetics Pharmaceuticals' insider trading history.
Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRNX Stock News Headlines

One tiny company just cracked Google’s $19B problem
For decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. Then an MIT team cracked the code… dropping the cost from $63,000 to just 90 cents per gram. Now, one US-based factory is gearing up to supply the AI, aerospace, and EV industries with the one material they can’t continue to grow without. Only one company controls it, and its stock is still flying under Main Street’s radar.tc pixel
See More Headlines

CRNX Stock Analysis - Frequently Asked Questions

Crinetics Pharmaceuticals' stock was trading at $51.13 at the start of the year. Since then, CRNX shares have decreased by 39.5% and is now trading at $30.92.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced its quarterly earnings data on Thursday, August, 7th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by $0.10. Crinetics Pharmaceuticals's quarterly revenue was up 158.4% on a year-over-year basis.
Read the conference call transcript
.

Crinetics Pharmaceuticals (CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Crinetics Pharmaceuticals' top institutional investors include State Street Corp (3.42%), Geode Capital Management LLC (2.36%), Jennison Associates LLC (2.12%) and Orbimed Advisors LLC (1.22%). Insiders that own company stock include Richard Scott Struthers, Marc Wilson, Stephen F Betz, Jeff E Knight, Dana Pizzuti, Alan Seth Krasner, James Hassard, Matthew K Fust, Stephanie Okey and Coelho Rogerio Vivaldi.
View institutional ownership trends
.

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Crinetics Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), ServiceNow (NOW) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
8/07/2025
Today
8/23/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRNX
CIK
1658247
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

High Price Target
$90.00
Low Price Target
$36.00
Potential Upside/Downside
+122.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$298.41 million
Net Margins
N/A
Pretax Margin
-26,568.53%
Return on Equity
-32.28%
Return on Assets
-29.45%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
17.80
Quick Ratio
17.80

Sales & Book Value

Annual Sales
$1.39 million
Price / Sales
2,091.90
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.44 per share
Price / Book
2.49

Miscellaneous

Outstanding Shares
94,176,000
Free Float
89,844,000
Market Cap
$2.91 billion
Optionable
Optionable
Beta
0.33

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:CRNX) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners